Scholarlink

Background <p>Chronic kidney disease (CKD) is slowly progressive, with clinically-relevant end-points of interest (e.g. kidney failure, dialysis, transplantation, death due to kidney disease) occurring many years after diagnosis, making the design of trials to evaluate treatments that slow the progression of kidney disease challenging. Recent meta-analyses have shown that the 3-year total slope of estimated glomerular filtration rate (eGFR) may serve as a reliable surrogate for these hard clinical outcomes. Existing research has focused on relaxing the linear trend assumption on the eGFR slope, accounting for informative censoring (via fitting a shared parameter model, for example), and evaluating heterogeneous treatment effects (HTEs) given predetermined subgroups. Yet, none have explored data-driven subgroup identification and HTE estimation.</p> Methods <p>We propose a Bayesian method that incorporates a Bayesian decision tree for HTE into a shared-parameter model that combines a survival model for censoring time with a two-slope spline model that characterizes the total eGFR slope. Our proposed approach simultaneously estimates the total eGFR slope in the presence of informative censoring and identifies interpretable subgroups of patients who experience differential treatment effects on the total eGFR slope outcome.</p> Results <p>Simulation studies demonstrate that our method accurately recovers treatment-effect heterogeneity with low estimation error, yielding better subgroup-specific treatment recommendations in moderate-to-large samples. Our method also controls false positives when no true heterogeneity presents. We apply our approach to the Modification of Diet in Renal Disease (MDRD) Trial, observing strong Bayesian evidence that patients with a baseline eGFR above 34.32 benefit more from the intensive systolic blood pressure control compared to patients with a baseline eGFR below 34.32. Specifically, the posterior probability that the treatment effect is larger in the higher-eGFR subgroup is 81 %.</p> Conclusion <p>Our proposed model can effectively capture even subtle HTEs while avoiding over-fitting when no heterogeneity exists, making it valuable for identifying HTE to inform downstream analyses such as treatment recommendations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Discovering heterogeneous treatment effects on slope-based endpoints in chronic kidney disease trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Tianyu Pan,
  • Lu Tian,
  • Manjula Kurella Tamura,
  • Maria Montez-Rath,
  • Vivek Charu

摘要

Background

Chronic kidney disease (CKD) is slowly progressive, with clinically-relevant end-points of interest (e.g. kidney failure, dialysis, transplantation, death due to kidney disease) occurring many years after diagnosis, making the design of trials to evaluate treatments that slow the progression of kidney disease challenging. Recent meta-analyses have shown that the 3-year total slope of estimated glomerular filtration rate (eGFR) may serve as a reliable surrogate for these hard clinical outcomes. Existing research has focused on relaxing the linear trend assumption on the eGFR slope, accounting for informative censoring (via fitting a shared parameter model, for example), and evaluating heterogeneous treatment effects (HTEs) given predetermined subgroups. Yet, none have explored data-driven subgroup identification and HTE estimation.

Methods

We propose a Bayesian method that incorporates a Bayesian decision tree for HTE into a shared-parameter model that combines a survival model for censoring time with a two-slope spline model that characterizes the total eGFR slope. Our proposed approach simultaneously estimates the total eGFR slope in the presence of informative censoring and identifies interpretable subgroups of patients who experience differential treatment effects on the total eGFR slope outcome.

Results

Simulation studies demonstrate that our method accurately recovers treatment-effect heterogeneity with low estimation error, yielding better subgroup-specific treatment recommendations in moderate-to-large samples. Our method also controls false positives when no true heterogeneity presents. We apply our approach to the Modification of Diet in Renal Disease (MDRD) Trial, observing strong Bayesian evidence that patients with a baseline eGFR above 34.32 benefit more from the intensive systolic blood pressure control compared to patients with a baseline eGFR below 34.32. Specifically, the posterior probability that the treatment effect is larger in the higher-eGFR subgroup is 81 %.

Conclusion

Our proposed model can effectively capture even subtle HTEs while avoiding over-fitting when no heterogeneity exists, making it valuable for identifying HTE to inform downstream analyses such as treatment recommendations.